Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Status:	Completed
Conditions:	Neurology, Neurology, Neurology
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	16 - 60
Updated:	7/19/2018
Start Date:	April 2008
End Date:	June 2010

A Multicenter, Open-label Extension Trial to Assess the Long-term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects With Partial-onset Seizures

The purpose of this study is to allow eligible subjects from the parent study, SP925
[NCT00655551] to continue lacosamide and to obtain additional long-term safety data

A multicenter, open-label extension study to assess the long-term safety and tolerability of
lacosamide as adjunctive therapy in subjects with partial-onset seizures who were previously
enrolled in the SP925 study [NCT00655551] (intravenous lacosamide loading dose followed by
approximately 1 week of oral lacosamide maintenance).

Inclusion Criteria:

- Eligible subjects who participated in SP925 [NCT00655551] for treatment of
partial-onset seizures

Exclusion Criteria:

- Receiving any study drug or experimental device other than lacosamide

- Meets withdrawal criteria for parent study SP925 [NCT00655551]

- Experiencing ongoing serious adverse event

We found this trial at

sites

Clinical Trial Facility in Baltimore Maryland

Baltimore, Maryland

from

Baltimore, MD